energy

RBC Capital keeps Outperform on Infinity Natural and Enerflex

RBC Capital maintained Outperform ratings on Infinity Natural with a $21 target and Enerflex with a $35 target. Reference data provided by Benzinga.

on the website stories appear 15 minutes after publication, in the api at once. connect the api →

what happened

RBC Capital kept its Outperform rating on Infinity Natural Resources shares with a price target of $21. The target implies a 51.2% upside from the October 13 close of $13.89. Analysts say the company stands out in the Appalachian Basin, where a balanced mix of oil and natural gas assets lets it shift development plans as commodity prices move. They also point to a strong balance sheet with low leverage and a sound hedging strategy.

For Enerflex, RBC Capital also maintained Outperform but set a $35 target. That level implies a 10.5% downside from the October 13 close of $39.11. Analysts highlight a power generation backlog above 1.75GW and a book-to-bill ratio of 1.6x in Engineered Systems bookings. They expect double-digit EBITDA growth in the coming years, and say higher 2028 estimates reflect confidence that margins can keep expanding.

The information comes from RBC Capital research, with reference data provided by Benzinga.

why it matters

For producers and energy equipment makers, these analyst calls serve as a signal for investors tracking demand for gas-fired power and data center infrastructure. Ratings and price targets do not guarantee share price moves, so they are best read alongside company reports and broader market conditions.

tags

instruments

Infinity Natural ResourcesEnerflex

sources

  1. RBC Capital maintains Outperform rating on Infinity Natural, $21 price target — Newsmetry API, 14 October 2026 at 13:32 UTC
  2. RBC Capital maintains Outperform rating on Enerflex, $35 price target — Newsmetry API, 14 October 2026 at 13:30 UTC
  3. RBC Capital maintains Outperform rating on Wells Fargo, $92 price target — Newsmetry API, 14 October 2026 at 13:44 UTC
  4. RBC Capital maintains Outperform rating on Revolution Medicines, $260 price target — Newsmetry API, 14 October 2026 at 13:40 UTC
  5. RBC Capital maintains Outperform rating on Kinetik Holdings, $58 price target — Newsmetry API, 14 October 2026 at 13:36 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

on the website stories appear 15 minutes after publication, in the api at once.

get stories in real time ↗